NCT04862780 2025-02-10(SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLCBlueprint Medicines CorporationPhase 1 Terminated177 enrolled
NCT03989115 2023-06-26Dose-Esc/Exp RMC4630 & Cobi in Relapsed/Refractory Solid Tumors & RMC4630& Osi in EGFR+ Locally Adv/Meta NSCLCRevolution Medicines, Inc.Phase 1/2 Completed113 enrolled 22 charts
NCT05153408 2023-06-18(HARMONY) Study of BLU-701 in EGFR-mutant NSCLCBlueprint Medicines CorporationPhase 1 Terminated20 enrolled